Chapter 4 Advances in cost-effectiveness analysis of health interventions

Handbook of Health Economics

Volumn 1, Issue PART A, 2000, Pages 181-221

  Garber, Alan M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

compensation princple; cost benefit; cost effectiveness; D61; H43; I11; I18; pharmacoeconomic; quality adjusted life years; sensitivity analysis; von Neumann Morgensterm utility; welfare economic

Indexed keywords

EID: 77956729661     PISSN: 15740064     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1574-0064(00)80163-8     Document Type: Chapter

References (41)

1. Barry M.J., Mulley Jr. A.G., Fowler F.J., and Wennberg J.E. Watchful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. Journal of the American Medical Association 259 (1988) 3010-3017
2. Birch S., and Gafni A. Cost-effectiveness ratios: in a league of their own. Health Policy 28 (1994) 133-141
3. Briggs A., and Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Economics 4 (1995) 355-371
4. Briggs A., Sculpher M., and Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics 3 (1994) 95-104
5. Chapter 32. Dolan P. The measurement of health-related quality of life for use in resource allocation decisions in health care. In: Newhouse J.P., and Culyer A.J. (Eds). Handbook of Health Economics (2000), Elsevier
6. Drummond M.F., O'Brien B., Stoddart G.L., and Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes (1997), Oxford University Press, Amsterdam
7. Drummond M.F., Stoddart G.L., and Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes (1987), Oxford University Press, New York
8. Finkler S.A. The distinction between cost and charges. Annals of Internal Medicine 96 (1982) 102-109
9. Fowler Jr. F.J., Wennberg J.E., Timothy R.P., Barry M.J., Mulley Jr. A.G., and Hanley D. Symptom status and quality of life following prostatectomy. Journal of the American Medical Association 259 (1988) 3018-3022
10. Gafni A., and Birch S. QALYs and HYEs (healthy years equivalent). Spotting the differences. Journal of Health Economics 16 (1997) 601-608
11. Garber A.M., Clarke A.E., Goldman D.P., and Gluck M.E. Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease (1992), Congress of the United States, Office of Technology Assessment, Oxford
12. Garber A.M., and Phelps C.E. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16 (1997) 1-31
13. Garber A.M., and Solomon N.A. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Annals of Internal Medicine 130 (1999) 719-728
14. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, Washington, DC
15. Hicks J.R. Foundations of welfare economics. Economic Journal 49 (1939) 696-712
16. Chapter 2. Hurley J. An overview of the normative economics of the health sector. In: Newhouse J.P., and Culyer A.J. (Eds). Handbook of Health Economics (2000), Elsevier, New York
17. Johannesson M., Pliskin J.S., and Weinstein M.C. Are healthy-years equivalents an improvement over quality-adjusted life years?. Medical Decision Making 13 (1993) 281-286
18. Johannesson M., and Weinstein M.C. On the decision rules of cost-effectiveness analysis. Journal of Health Economics 12 (1993) 459-467
19. Kaldor N. Welfare propositions of economics and interpersonal comparisons of utility. Economic Journal 49 (1939) 549-552
20. Karlsson G., and Johannesson M. The decision rules of cost-effectiveness analysis. PharmacoEconomics 9 (1996) 113-120
21. Keeney R.L., and Raiffa H. Decisions with Multiple Objectives (1993), Cambridge University Press, Amsterdam
22. Kenkel D.S. On valuing morbidity, cost-effectiveness analysis, and being rude. Journal of Health Economics 16 (1997) 749-757
23. Luce B.R., Manning W.G., Siegel J.E., and Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, Cambridge 176-213
24. Mark D.B., Hlatky M.A., Califf R.M., Naylor C.D., Lee K.L., Armstrong P.W., Barbash G., White H., Simoons M.L., and Nelson C.L. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New England Journal of Medicine 332 (1995) 1418-1424
25. Mehrez A., and Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Medical Decision Making 9 (1989) 142-149
26. Mehrez A., and Gafni A. Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress. Medical Decision Making 13 (1993) 287-292
27. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. Journal of Health Economics 16 (1997) 33-64
28. Mullahy J., and Manning W.G. Statistical issues in cost-effectiveness analysis. In: Sloan F. (Ed). Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies (1994), Cambridge University Press, New York
29. O'Brien B.J., Drummond M.F., Labelle R.J., and Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Medical Care 32 (1994) 150-163
30. Patrick D.L., and Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation (1993), Oxford University Press, New York
31. Pauly M.V. The economics of moral hazard: comment. American Economic Review 58 (1968) 531-537
32. Pauly M.V. Valuing health care benefits in money terms. In: Sloan F. (Ed). Valuing Health Care: Costs, Benefits, and Effectiveness of Medical Technologies (1995), Cambridge University Press, New York 99-124
33. Phelps C.E., and Mushlin A.I. On the (near) equivalence of cost effectiveness and cost benefit analysis. International Journal of Technology Assessment in Health Care 7 (1991) 12-21
34. Rawls J. A Theory of Justice (1971), Harvard University Press, Cambridge
35. Russell L.L. Is Prevention Better than Cure? (1986), The Brookings Institution, Cambridge, MA
36. Schelling T.C. The life you save may be your own. Problems in Public Expenditure Analysis (1968), The Brookings Institution, Washington, DC 127-159
37. Siegel J.E., Weinstein M.C., and Torrance G.W. Reporting cost-effectiveness studies and results. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, Washington, DC 276-303
38. US Congress Office of Technology Assessment. The Implications of Cost-Effectiveness Analysis of Medical Technology (1980), US Government Printing Office, New York
39. US Congress Office of Technology Assessment. Pharmaceutical R&D: Costs, Risks and Rewards, OTA-H-522 (1993), US Government Printing Office, Washington, DC
40. Wakker P., and Klaassen M.P. Confidence intervals for cost/effectiveness ratios. Health Economics 4 (1995) 373-381
41. Weinstein M.C., and Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296 (1977) 716-721